دورية أكاديمية
أعرض في EDS

Growth differentiation factor 15 is not modified after weight loss induced by liraglutide in South Asians and Europids with type 2 diabetes mellitus.

التفاصيل البيبلوغرافية
العنوان: Growth differentiation factor 15 is not modified after weight loss induced by liraglutide in South Asians and Europids with type 2 diabetes mellitus.
المؤلفون: Hoekx CA; Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands., Straat ME; Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands., Bizino MB; Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.; Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands., van Eyk HJ; Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands., Lamb HJ; Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands., Smit JWA; Department of Medicine, Radboud University Medical Center, Nijmegen, The Netherlands., Jazet IM; Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands., de Jager SCA; Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands., Boon MR; Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands., Martinez-Tellez B; Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands.; Department of Nursing Physiotherapy and Medicine, SPORT Research Group (CTS-1024), CERNEP Research Center, University of Almería, Almería, Spain.; Biomedical Research Unit, Torrecárdenas University Hospital, Almería, Spain.; CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Granada, Spain.
المصدر: Experimental physiology [Exp Physiol] 2024 Aug; Vol. 109 (8), pp. 1292-1304. Date of Electronic Publication: 2024 Jul 04.
نوع المنشور: Journal Article; Randomized Controlled Trial
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9002940 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1469-445X (Electronic) Linking ISSN: 09580670 NLM ISO Abbreviation: Exp Physiol Subsets: MEDLINE
أسماء مطبوعة: Publication: Cambridge, Eng : Wiley-Blackwell
Original Publication: Cambridge ; New York, NY, USA : Published for the Physiological Society by Cambridge University Press, c1990-
مواضيع طبية MeSH: Liraglutide*/therapeutic use , Liraglutide*/pharmacology , Growth Differentiation Factor 15*/blood , Diabetes Mellitus, Type 2*/drug therapy , Diabetes Mellitus, Type 2*/blood , Weight Loss*/drug effects , Metformin*/therapeutic use , Metformin*/pharmacology , Hypoglycemic Agents*/therapeutic use , Hypoglycemic Agents*/pharmacology , Asian People*, Humans ; Male ; Female ; Middle Aged ; Aged ; Glucagon-Like Peptide-1 Receptor/agonists ; Glucagon-Like Peptide-1 Receptor/metabolism ; South Asian People
مستخلص: Glucagon-like peptide-1 receptor (GLP-1R) agonists induce weight loss in patients with type 2 diabetes mellitus (T2DM), but the underlying mechanism is unclear. Recently, the mechanism by which metformin induces weight loss could be explained by an increase in growth differentiation factor 15 (GDF15), which suppresses appetite. Therefore, we aimed to investigate whether the GLP-1R agonist liraglutide modifies plasma GDF15 levels in patients with T2DM. GDF15 levels were measured in plasma samples obtained from Dutch Europids and Dutch South Asians with T2DM before and after 26 weeks of treatment with daily liraglutide (n = 44) or placebo (n = 50) added to standard care. At baseline, circulating GDF15 levels did not differ between South Asians and Europids with T2DM. Treatment with liraglutide, compared to placebo, decreased body weight, but did not modify plasma GDF15 levels in all patients, or when data were split by ethnicity. Also, the change in plasma GDF15 levels after treatment with liraglutide did not correlate with changes in body weight or HbA 1c levels. In addition, the dose of metformin used did not correlate with baseline plasma GDF15 levels. Compared to placebo, liraglutide treatment for 26 weeks does not modify plasma GDF15 levels in Dutch Europid or South Asian patients with T2DM. Thus, the weight loss induced by liraglutide is likely explained by other mechanisms beyond the GDF15 pathway. HIGHLIGHTS: What is the central question of this study? Growth differentiation factor 15 (GDF15) suppresses appetite and is increased by metformin: does the GLP-1R agonist liraglutide modify plasma GDF15 levels in patients with type 2 diabetes mellitus (T2DM)? What is the main finding and its importance? Plasma GDF15 levels did not differ between South Asians and Europids with T2DM and were not modified by 26 weeks of liraglutide in either ethnicity. Moreover, there was no correlation between the changes in plasma GDF15 levels and dosage of metformin administered, changes in body weight or HbA1c levels. The appetite-suppressing effect of liraglutide is likely exerted via pathways other than GDF15.
(© 2024 The Author(s). Experimental Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society.)
References: Mol Pharmacol. 2001 Apr;59(4):901-8. (PMID: 11259636)
Diabetes Care. 2012 Apr;35(4):731-7. (PMID: 22442396)
Diabetes Care. 2010 Jul;33(7):1629-34. (PMID: 20413520)
Diabetes. 2017 Nov;66(11):2774-2788. (PMID: 28874416)
Nat Rev Endocrinol. 2021 Jun;17(6):364-377. (PMID: 33948015)
Metabolism. 2020 May;106:154167. (PMID: 31982480)
Diabetes Metab J. 2014 Dec;38(6):472-9. (PMID: 25541611)
Diabetologia. 2011 Dec;54(12):3022-7. (PMID: 21959957)
Indian J Endocrinol Metab. 2015 Jan-Feb;19(1):30-8. (PMID: 25593823)
Diabetes Metab Syndr. 2016 Jan-Mar;10(1 Suppl 1):S154-7. (PMID: 26482961)
N Engl J Med. 2006 Dec 7;355(23):2427-43. (PMID: 17145742)
Diabetologia. 2020 Jan;63(1):65-74. (PMID: 31690988)
Mol Metab. 2015 Aug 05;4(10):718-31. (PMID: 26500843)
Cardiovasc Diabetol. 2019 Jul 9;18(1):87. (PMID: 31288820)
Obesity (Silver Spring). 2015 Mar;23(3):699-706. (PMID: 25645144)
Diabetes Care. 2019 May;42(5):946-953. (PMID: 30796111)
J Diabetes Res. 2015;2015:490842. (PMID: 26273671)
Nat Med. 2017 Oct;23(10):1215-1219. (PMID: 28846098)
Lancet. 1991 Feb 16;337(8738):382-6. (PMID: 1671422)
Oncol Lett. 2023 Sep 13;26(5):462. (PMID: 37780545)
Metabolism. 2022 Aug;133:155237. (PMID: 35700837)
Obes Res. 1998 Jan;6(1):47-53. (PMID: 9526970)
Int J Endocrinol. 2017;2017:9401606. (PMID: 29358950)
Elife. 2020 Jul 29;9:. (PMID: 32723474)
Cell Metab. 2018 Apr 3;27(4):740-756. (PMID: 29617641)
Eur J Endocrinol. 2013 Oct 01;169(5):R99-R114. (PMID: 23939919)
Int J Mol Sci. 2023 Jan 23;24(3):. (PMID: 36768561)
J Neurogastroenterol Motil. 2011 Oct;17(4):338-48. (PMID: 22148102)
Diabetes Metab Syndr Obes. 2021 Aug 10;14:3567-3602. (PMID: 34413662)
JAMA. 2013 Nov 27;310(20):2191-4. (PMID: 24141714)
Cancer Med. 2021 May;10(9):3013-3025. (PMID: 33784024)
J Diabetes Investig. 2022 Jul;13(7):1149-1160. (PMID: 35191185)
Obes Facts. 2024;17(1):1-11. (PMID: 37989122)
Expert Opin Ther Targets. 2022 Jan;26(1):57-67. (PMID: 35138971)
Nat Metab. 2019 Dec;1(12):1202-1208. (PMID: 32694673)
Metabolites. 2019 Apr 13;9(4):. (PMID: 31013892)
Diabetes Care. 2022 Jan 1;45(Suppl 1):S125-S143. (PMID: 34964831)
Pharmacol Res. 2021 Sep;171:105782. (PMID: 34302978)
Nature. 2017 Oct 12;550(7675):255-259. (PMID: 28953886)
Nat Commun. 2018 Jan 9;9(1):113. (PMID: 29317623)
Nature. 2020 Feb;578(7795):444-448. (PMID: 31875646)
Exp Physiol. 2024 Aug;109(8):1292-1304. (PMID: 38965822)
Nat Med. 2017 Oct;23(10):1150-1157. (PMID: 28846097)
Nat Med. 2017 Oct;23(10):1158-1166. (PMID: 28846099)
Diabetes. 2014 Mar;63(3):880-91. (PMID: 24270984)
Mol Metab. 2019 Mar;21:13-21. (PMID: 30685336)
Cell Metab. 2023 Feb 7;35(2):274-286.e10. (PMID: 36630958)
Nature. 2023 Jul;619(7968):143-150. (PMID: 37380764)
BMC Nephrol. 2020 Sep 29;21(1):415. (PMID: 32993549)
Nature. 2000 Apr 6;404(6778):635-43. (PMID: 10766250)
Acta Diabetol. 2021 Apr;58(4):485-493. (PMID: 33399989)
Cardiovasc Diabetol. 2019 Apr 30;18(1):55. (PMID: 31039778)
Exp Diabetes Res. 2011;2011:279530. (PMID: 21747825)
معلومات مُعتمدة: 09150161910073 Dutch Research Council NWO; RR_C_2021_04 Ministerio de Universidades y la Unión Europea-NextGenerationEU
فهرسة مساهمة: Keywords: ethnic differences; metabolic diseases; obesity; weight‐reducing drugs
المشرفين على المادة: 839I73S42A (Liraglutide)
0 (Growth Differentiation Factor 15)
0 (GDF15 protein, human)
9100L32L2N (Metformin)
0 (Hypoglycemic Agents)
0 (Glucagon-Like Peptide-1 Receptor)
تواريخ الأحداث: Date Created: 20240705 Date Completed: 20240801 Latest Revision: 20240803
رمز التحديث: 20240803
مُعرف محوري في PubMed: PMC11291866
DOI: 10.1113/EP091815
PMID: 38965822
قاعدة البيانات: MEDLINE
الوصف
تدمد:1469-445X
DOI:10.1113/EP091815